ecrin-mdr-crcClinical2020HER2-positive Colorectal CancerEndometrial CancerGastrointestinal CancerHead and Neck CancerColorectal CancerEndometrial NeoplasmsBreast CancerHER2-positive Breast CancerNon-Small Cell Lung CancerHER2-positive Solid TumorsGastric CancerColorectal NeoplasmsHER2-positive Gastroesophageal CancerHER2-positive Endometrial CancerEndometrial CancerGastrointestinal CancerColorectal CancerEndometrial NeoplasmsBreast CancerHer2-positive Solid TumorsHer2-positive Endometrial CancerHer2-positive Colorectal CancerGastric CancerNon-small Cell Lung CancerColorectal NeoplasmsHer2-positive Gastroesophageal CancerHead And Neck CancerHer2-positive Breast CancerInterventionalhttps://newmdr.ecrin.org/Study/2330766South KoreaUnited StatesSpain2Stomach CancerGastroesophageal junctionUrothelial CancerTLR7/8 agonistBiliary Tract CancerImmunotherapyNivolumabERBB2HER2ECRIN MDRRecruitingfalseA First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsA first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies2020-02-152330766NCT04278144